^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MIR23b (MicroRNA 23b)

    i
    Other names: MIR23b, miR-23b, MicroRNA 23b, Hsa-MiR-23b-5p, Hsa-MiR-23b-3p, Hsa-Mir-23b, MIR23B, Hsa-Mir-23-P2, MIMAT0000418, MIMAT0004587, MI0000439, MiRNA23B, MIRN23B, Mir-23b, RF00642
    14d
    Gene Expression Profiling to Unveil Novel Biomarkers for Early Diagnosis and Therapies for Breast Cancer. (PubMed, Curr Top Med Chem)
    The stability of the top three receptor-ligand complexes was validated through molecular dynamics simulations. Therefore, our findings could be a valuable resource for researchers and medical professionals, aiding in BC diagnosis and treatment.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CAV1 (Caveolin 1) • MIR155 (MicroRNA 155) • CD34 (CD34 molecule) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CD36 (thrombospondin receptor) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CD31 (Platelet and endothelial cell adhesion molecule 1) • MIR16 (MicroRNA 16) • MIR23b (MicroRNA 23b) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
    |
    Lynparza (olaparib) • lapatinib • Verzenio (abemaciclib) • Tukysa (tucatinib)
    1m
    Comparative miRNA Expression Profiling Reveals Candidates Involved in Prostate Cancer Radioresistance. (PubMed, APMIS)
    Distinct mirna signatures differentiate radiation-resistant and radiation-sensitive prostate cancer cells. Mir-20a-5p, mir-128-3p, and mir-135b-5p may contribute to radioresistance, whereas mir-23b-3p and mir-381-3p may act as radiosensitizers.
    Clinical • Journal
    |
    MIR135B (MicroRNA 135b) • MIR23b (MicroRNA 23b) • MIR381 (MicroRNA 381) • MIR128 (MicroRNA 128) • MIR20A (MicroRNA 20a)
    1m
    Differentially Expressed Genes Associated with the Development of Cervical Cancer. (PubMed, Int J Mol Sci)
    The publicly available microarray datasets, including GSE39001, GSE9750, GSE7803, GSE6791, GSE63514, and GSE52903 in combination with bioinformatics database predictions, were used to identify differential expression genes, potential biomarkers, and therapeutic targets for cervical cancer; additionally, we undertook bioinformatic analysis to determine gene ontology and possible miRNA targets related to our DEGs...Interestingly, hub proteins KIF4A, NUSAP1, BUB1B, CEP55, DLGAP5, NCAPG, CDK1, MELK, KIF11, and KIF20A were found to be potentially regulated by several miRNAs, including miR-107, miR-124-3p, miR-147a, miR-16-5p, miR-34a-5p, miR-34c-5p, miR-126-3p, miR-10b-5p, miR-23b-3p, miR-200b-3p, miR-138-5p, miR-203a-3p, miR-214-3p, and let-7b-5p. The relationship between these genes highlights their potential as candidate biomarkers for further research in treatment, diagnosis, and prognosis.
    Journal
    |
    TP53 (Tumor protein P53) • TOP2A (DNA topoisomerase 2-alpha) • RAD51 (RAD51 Homolog A) • MIR200B (MicroRNA 200b) • MIR34A (MicroRNA 34a-5p) • RAD51AP1 (RAD51 Associated Protein 1) • NUSAP1 (Nucleolar and Spindle Associated Protein 1) • ELF3 (E74 Like ETS Transcription Factor 3) • FOXM1 (Forkhead Box M1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • MIR126 (MicroRNA 126) • MIR16 (MicroRNA 16) • MIR23b (MicroRNA 23b) • NCAPG (Non-SMC Condensin I Complex Subunit G) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CEP55 (Centrosomal Protein 55) • CXCL14 (C-X-C Motif Chemokine Ligand 14) • E2F1 (E2F transcription factor 1) • KIF20A (Kinesin Family Member 20A) • KIF4A (Kinesin Family Member 4A) • MCM2 (Minichromosome maintenance complex component 2) • MCM5 (Minichromosome Maintenance Complex Component 5) • MIR10B (MicroRNA 10b) • MIR138 (MicroRNA 138) • MIR203A (MicroRNA 203a) • MIR214 (MicroRNA 214) • MIRLET7B (MicroRNA Let-7b) • RELA (RELA Proto-Oncogene) • RFC4 (Replication Factor C Subunit 4) • MIR124-3 (MicroRNA 124-3)
    2ms
    MicroRNAs in Prostate Cancer Liquid Biopsies: Early Detection, Prognosis, and Treatment Monitoring. (PubMed, Cells)
    Although promising, clinical implementation of miRNA-based assays requires further validation, standardization of protocols, and large-scale prospective studies. Harnessing circulating miRNAs could usher in a new era of precision oncology for PCa, improving early diagnosis, prognostication, and real-time therapeutic guidance.
    Review • Journal • Liquid biopsy
    |
    MIR200B (MicroRNA 200b) • MIR21 (MicroRNA 21) • MIR141 (MicroRNA 141) • MIR23b (MicroRNA 23b) • MIR375 (MicroRNA 375) • MIR20A (MicroRNA 20a) • MIR326 (MicroRNA 326)
    2ms
    Mesenchymal stem cell-derived extracellular vesicle therapy in breast cancer: A systematic review and meta-analysis of in vitro studies. (PubMed, Mol Ther Oncol)
    Precision engineering of MSC-EVs can enhance antitumor activity but requires stringent cargo control to avoid dormancy risks. Only in vitro data were quantitatively analyzed, while in vivo findings were discussed for mechanistic context, providing a methodological foundation for future translational research.
    Preclinical • Retrospective data • Review • Journal
    |
    MIR23b (MicroRNA 23b)
    2ms
    Role of EpCAM-Positive Exosomes in Ovarian Cancer: MiRNA Signatures of Chemoresistance and Disease Progression. (PubMed, Asia Pac J Clin Oncol)
    Overall, the study highlights a probable mechanism for miRNA packaging and release in OC through EpCAM-positive exosomes, offering potential biomarkers for monitoring disease progression and relapse.
    Journal
    |
    EPCAM (Epithelial cell adhesion molecule) • MIR182 (MicroRNA 182) • MIR23b (MicroRNA 23b) • MIR130A (MicroRNA 130a) • MIR20A (MicroRNA 20a)
    6ms
    Chemotherapy-induced alterations in miRNA expression and their prognostic implications in ovarian cancer. (PubMed, Front Oncol)
    The study highlights differential regulation of circulating and tissue miRNAs in Indian OC patients, emphasizing the selective retention of oncogenic miRNAs in tumors and release of tumor suppressive miRNAs into circulation. These findings support the utility of miRNAs as diagnostic and prognostic biomarkers in OC.
    Journal
    |
    MIR200A (MicroRNA 200a) • MIR106A (MicroRNA 106a) • MIR182 (MicroRNA 182) • MIR23b (MicroRNA 23b) • MIR130A (MicroRNA 130a) • MIR145 (MicroRNA 145) • MIR20A (MicroRNA 20a) • MIR433 (MicroRNA 433)
    6ms
    Unveiling the role of RAI14 in cancer: Biological significance and translational perspectives. (PubMed, Semin Oncol)
    Targeting RAI14 as a cancer antigen can also potentially help halt tumor progression. Future large-scale trials are needed to confirm the tumor-regulatory role of RAI14 in human cancer and to evaluate the sensitivity, reliability, and accuracy of using this target as a biomarker or therapeutic target.
    Review • Journal
    |
    mTOR (Mechanistic target of rapamycin kinase) • AFAP1-AS1 (AFAP1 Antisense RNA 1) • RAI1 (Retinoic Acid Induced 1) • MIR23b (MicroRNA 23b)
    6ms
    Plasma exosomal miR-122-5p_R-1, miR-23b-3p_R + 1, and miR-15a-5p_R-1 are associated with multidrug-resistant tuberculosis. (PubMed, BMC Infect Dis)
    We suggest that hsa-miR-122-5p_R-1, hsa-miR-23b-3p_R + 1, and hsa-miR-15a-5p_R-1 are closely related to MDR-TB.
    Journal
    |
    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • ATF6 (Activating Transcription Factor 6) • KIDINS220 (Kinase D Interacting Substrate 220) • MIR23b (MicroRNA 23b) • MAPK9 (Mitogen-Activated Protein Kinase 9) • MIR122 (MicroRNA 122) • MIR15A (MicroRNA 15a)
    6ms
    A Brief Review of MicroRNA Profiling in Human Prostate Cancer Tissues and Plasma. (PubMed, Biomolecules)
    Two miRNAs-miR-449b and miR-455-3p-were common in both compartments, highlighting their translational potential as liquid biopsy surrogates of tumor biology. (4) We summarize functional evidence for leading tumor-suppressive (e.g., miR-205, miR-23b, miR-455-3p) and oncogenic (e.g., miR-21, miR-182, miR-449b) candidates, discuss their intersection with the androgen-receptor, TGF-β, WNT/β-catenin, and PI3K-AKT signaling, and outline outstanding requirements for the clinical qualification of miRNA panels in prostate cancer.
    Review • Journal
    |
    AR (Androgen receptor) • MIR21 (MicroRNA 21) • TGFB1 (Transforming Growth Factor Beta 1) • MIR182 (MicroRNA 182) • MIR23b (MicroRNA 23b) • MIR205 (MicroRNA 205) • MIR455 (MicroRNA 455)
    7ms
    Determination of longitudinal Circulating levels of miR-21-5p, miR-23b-3p and miR-34a-5p in plasma of patients with glioblastoma using droplet digital PCR. (PubMed, Neurosurg Rev)
    Although the diagnostic performance of miR-34a-5p was intermediate and the small cohort size limited definitive conclusions, these preliminary findings support further exploration of these miRNAs as part of a multi-marker panel to enhance diagnostic and prognostic accuracy in GBM. Larger, prospective studies are required to validate these results and to elucidate the biological underpinnings of peripheral miRNA dynamics in the context of GBM pathophysiology and treatment.
    Journal
    |
    MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • MIR23b (MicroRNA 23b)
    7ms
    Meta-analysis and Database Validation of Exosomal MicroRNAs and Prognosis in Gastric Cancer Patients. (PubMed, Curr Med Chem)
    These findings align with prior studies highlighting the role of specific miRNAs in tumor progression but diverge regarding their diagnostic utility for clinicopathological features. Future research should explore the functional mechanisms of these miRNAs in GC biology and validate their prognostic value in larger, diverse cohorts to inform personalized treatment strategies.
    Retrospective data • Journal
    |
    MIR100 (MicroRNA 100) • MIR23b (MicroRNA 23b) • MIR30A (MicroRNA 30a) • MIR134 (MicroRNA 134)